Welcome back no_ur_stox,
Pretty much my thoughts too, however I can see Blue's point also.
I have around 290k shares in a UK company called Valirx.
Their mo is to develop therapies for oncology indications and then license or partner the successful ones. They passed phase 2 one one and the pps shot up, released data on the phase 1/2 and price shot up again.
That is their mo and they are considered to be undervalued over here too.
Pluristem have always had the desire to become 'Big Pharma' in their own right and I understand that. However, they should think of their shareholders also and maybe, perhaps license out one of their therapies, get some dollars in the bank, enough for at least two or three years clinical testing and admin burn, then persue their dream.
Just my honest opinion